文献速递肝病

肝硬度测量动态变化与原发性胆汁性胆管炎的临床病程

Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-07-15

这项国际回顾性队列研究纳入3078例接受熊去氧胆酸治疗的原发性胆汁性胆管炎患者,2003至2022年间共完成6362次振动控制瞬时弹性成像肝硬度测量。联合模型分析显示,校正基线预后因素后,肝硬度任何相对变化均与严重临床事件风险显著相关(P < .001)。

要点

  • 肝硬度每年增加20%时,严重临床事件 adjusted HR 为2.13(95%CI 1.89-2.45)。
  • 肝硬度每年降低20%时,严重临床事件 adjusted HR 为0.40(95%CI 0.33-0.46)。
  • 肝硬度轨迹与严重临床事件风险的关联在排除肝硬化患者后仍持续存在。

核心结论

  • 纵向追踪振动控制瞬时弹性成像肝硬度变化可为原发性胆汁性胆管炎预后提供有价值的信息,是严重临床事件风险的稳健预测指标。
  • 肝硬度可作为原发性胆汁性胆管炎临床试验中具有临床相关性的替代终点。

研究设计与样本

  • 国际回顾性队列研究,纳入2003至2022年间接受熊去氧胆酸治疗并接受振动控制瞬时弹性成像随访的原发性胆汁性胆管炎患者。
  • 共3078例患者,其中2007例单用熊去氧胆酸,13%有肝硬化;共完成6362次肝硬度测量。

主要发现

  • 中位随访4.2年,共发生316例严重临床事件,总随访14445人年,发生率21.9/1000人年。
  • 59%的患者肝硬度进展,平均每年0.39 kPa。
  • 校正基线预后因素(包括肝硬度)后,肝硬度任何相对变化均与严重临床事件风险显著变化相关(P < .001)。
  • 肝硬度每年增加20%对应的校正HR为2.13(95%CI 1.89-2.45),每年降低20%对应的校正HR为0.40(95%CI 0.33-0.46)。
  • 无论治疗应答或疗程如何、排除肝硬化患者后、或仅考虑死亡或肝移植时,肝硬度轨迹与严重临床事件风险的关联均持续存在。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: In primary biliary cholangitis (PBC), static liver stiffness measurement (LSM) has proven prognostic value. However, the added prognostic value of LSM time course in this disease remains uncertain. METHODS: We conducted an international retrospective cohort study among patients with PBC treated with ursodeoxycholic acid and followed by vibration-controlled transient elastography between 2003 and 2022. Using joint modeling, the association of LSM trajectory and the incidence of serious clinical events (SCE), defined as cirrhosis complications, liver transplantation, or death, was quantified using the hazard ratio and its confidence interval. RESULTS: A total of 6362 LSMs were performed in 3078 patients (2007 on ursodeoxycholic acid alone; 13% with cirrhosis), in whom 316 SCE occurred over 14,445 person-years (median follow-up, 4.2 years; incidence rate, 21.9 per 1000 person-years). LSM progressed in 59% of patients (mean, 0.39 kPa/year). After adjusting for prognostic factors at baseline, including LSM, any relative change in LSM was associated with a significant variation in SCE risk (P < .001). For example, the adjusted hazard ratios (95% confidence interval) associated with a 20% annual variation in LSM were 2.13 (1.89-2.45) for the increase and 0.40 (0.33-0.46) for the decrease. The association between LSM trajectory and SCE risk persisted regardless of treatment response or duration, when patients with cirrhosis were excluded, and when only death or liver transplantation was considered. CONCLUSIONS: Tracking longitudinal changes in LSM using vibration-controlled transient elastography provides valuable insights into PBC prognosis, offering a robust predictive measure for the risk of SCE. LSM could be used as a clinically relevant surrogate end point in PBC clinical trials.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Lam L, Soret PA, Lemoinne S, et al. Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis. Clin Gastroenterol Hepatol. 2024. PMID: 39019421. doi:10.1016/j.cgh.2024.06.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。